Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGRESS phase 2 trial of INCB000928 in fibrodysplasia ossificans progressiva
NL-OMON59934Phase 2Recruiting
- Sponsor
- Incyte
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing INCB000928 with Placebo then crossover to INCB000928 (2 arms). Primary endpoint: Occurrence of new heterotopic ossification lesions from baseline to Week 24. Started Aug 2024; status: recruiting.
02
Drugs
zilurgisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NL-OMON59934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59934.